Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.
After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?
Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.
Shareholders would be well-served by the pharmacy benefit managers' merger, but regulators are unlikely to sign off on it, says Morningstar's Matt Coffina.
Charles Schwab announced Monday that it has joined with Piper Jaffray to provide clients access to Piper Jaffray's new issue municipal bonds through Schwab's BondSource Platform.
New products introduced over the last week include an arrangement between Schwab and Piper Jaffray to provide investors greater access to the latter’s new muni bonds; more.
Deal expands universe of issues available to Schwab clients via BondSource.
Good morning, ladies and gentlemen, and welcome to the Piper Jaffray Companies conference call to discuss the financial results for the third quarter of 2011.
©2012 Morningstar Advisor. All right reserved.